Schedule Now
Schedule Now

Non-Invasive Pregnancy Screening (NIPS)

With just a single blood draw, this cutting-edge technology ensures a remarkably low test failure rate (1-3). AssurePS utilizes advanced sequencing technology, delivering precise and reliable information for pregnant patients, irrespective of age or risk factors. Trust in AssurePS to provide accurate insights, empowering expectant individuals with valuable knowledge about their pregnancy early on.


NIPS vs. Traditional Serum Screening

Offers the highest reported detection rate for Down syndrome (5). Offers the lowest reported false positive rate for Down syndrome (5). Offers the broadest screening window (performed as early as 10 weeks gestation until term) (5).

  • AssurePS
    • Trisomy 21 (Down syndrome) 
    • Trisomy 18 (Edwards syndrome) 
    • Trisomy 13 (Patau syndrome) Sex chromosome aneuploidies 
    • Monosomy X (MX/Turner syndrome) 
    • XXX (Triple X) XXY (Klinefelter syndrome) 
    • XYY (Jacob’s syndrome) 
    • Fetal Sex prediction may be reported if no sex chromosome aneuploidies are detected
  • AssurePlus
    • AssurePlus offers an expanded elective panel, encompassing rare autosomal trisomies and clinically significant microdeletions, providing enhanced insights.
    • Obtain reliable results without resorting to invasive procedures, ensuring the secure acquisition of critical information pertaining to your pregnancy.
    • Rely upon our proven technology utilizing QLabs' next-generation sequencing, widely acknowledged as the industry standard for its capacity to deliver precise and dependable results (5).
    • Explore additional panel options extending beyond common trisomy screenings, allowing for a tailored testing experience to meet specific individual requirements.

It Matters Where You Test

  • Improved performance compared to traditional screening methods for the screening of common fetal aneuploidies, with reduced false positive rates (increased specificity) and increased positive predictive values (PPV) (6,7). 
  • Comprehensive portfolio with an expanded panel available 
  • Fast turnaround time (8). Proceed with confidence of a low failure rate of 0.6% (1).
View more
Woman smiling on phone

References:  

  1. Data on file. Illumina, Inc 2022
  2. McCullough RM, Almasri EA, Guan X, et al. Non-invasive prenatal chromosomal aneuploidy testing—clinical experience: 100,000 clinical samples. PLoS One. 2014;9(10):e109173.
  3. Dar, Pe’er et al. Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. Am. J. Obstet. Gynecol. (2022) doi:10.1016/j.ajog.2022.01.019
  4. Mossfield T, Soster E, Menezes M, Agenbag G, Dubois M-L, Gekas J, Hardy T, Jurkowska M, Kleinfinger P, Loggenberg K, Marchili P and Sirica R (2022), Multisite assessment of the impact of cell-free DNA-based screening for rare autosomal aneuploidies on pregnancy management and outcomes. Front. Genet. 13:975987. doi: 10.3389/fgene.2022.975987
  5. Data calculation on file. Illumina, Inc. 2022.
  6. Rose, N. C. et al. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. Obstet. Gynecol.136, e48–e69 (2020).
  7. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370(9):799-808.
  8. Taneja PA, Snyder HL, de Feo E, et al. Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85 000 cases. Prenat Diagn. 2016;36(3):237-243.

Schedule a Time for a Consultation